Nichirin Co., Ltd.

2026/02/13 Updated
Market Cap: $338.2M (¥51.7B)
Stock Price: $25.64 (¥3,920)
Exchange Rate: 1 USD = ¥152.91

Notice Regarding Change in Shareholder Return Policy

From the fiscal year ending December 2026, the consolidated payout ratio target will be raised from 40% to 45%, and the share buyback framework for 2026 to 2028 will be expanded to a total of 4 billion yen, revising the shareholder return policy.

Importance:
Page Updated: February 13, 2026
IR Disclosure Date: February 13, 2026

Key Figures

  • Consolidated Payout Ratio Target: 45% (from fiscal year 2026 onward)
  • Share Buyback Framework: Total of 4 billion yen (over three years from 2026 to 2028)
  • Start of Application: Fiscal Year 2026 (FY ending December 2026)

AI要約

Overview of Changes in Shareholder Return Policy

Nichirin Co., Ltd. resolved at its Board of Directors meeting on February 13, 2026, to revise its shareholder return policy. Under the new policy, the consolidated payout ratio target will be raised to 45% from fiscal year 2026 onward, and the share buyback framework will be expanded to a total of 4 billion yen over three years from 2026 to 2028. Previously, the share buyback framework was set at a total of 1 billion yen over two years from 2024 to 2025. This revision aims to strengthen management that pays close attention to capital cost and stock price, thereby enhancing shareholder returns.

Impact on Shareholders and Application Timing

The revised shareholder return policy will be applied from fiscal year 2026 (FY ending December 2026). While maintaining stable dividend payments as a basic principle, the policy sets a lower limit of 2.5% DOE (Dividend on Equity) and strives to increase total shareholder returns. The expansion of share buybacks is expected to improve market liquidity and enhance shareholder value, although specific details regarding the number of shares or dilution ratio are not provided.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.